Zentrum für Epidemiologie und Gesundheitsforschung
Our most recent INAS-SCORE publication has been selected as a ‘highlighted’ article for this month’s edition of the European Journal of Contraception and Reproductive Health.
The article will be freely available to download next month (August 2019), via this link: https://doi.org/10.1080/13625187.2019.1629412 
You are very welcome to download a full-text personal copy of the article, next month (August 2019) as an open-access article.
Yesterday, our latest publication, Unintended pregnancy rates differ according to combined oral contraceptive – results from the INAS-SCORE study was published online in the European Journal of Contraception and Reproductive Health Care.
The study was aimed at estimating the real-use contraceptive effectiveness of the combined oral contraceptive (COC) containing dienogest and oestradiol valerate (DNG/oEV) compared to other combined oral contraceptives (
The results confirmed that DNG/oEV showed improved contraceptive effectiveness compared with oCOC and particularly LNG-COC when adjusted for age, parity, user status, and smoking
Our latest publication, Real-world data on Nexplanon® procedure-related events: final results from the Nexplanon observational risk assessment study (NORA) has just been published in Contraception.
The study was aimed to characterize the frequency of
The finds confirmed that events associated with the insertion, localization, and removal of the Nexplanon contraceptive implant were rare and their clinical consequences were generally not suggestive of serious injury.
The study demonstrates that complications associated with insertion and removal of Nexplanon are rare when performed by trained clinicians.
Congratulations to our Project Management team! This October 2018 they will be headed to Rio de Janeiro, Brazil to present at the FIGO XXII RIO World Congress of Gynecology and Obstetrics. We are proud to announce that eight of our abstracts were accepted; seven oral presentations and one poster for the poster session on October 16, 2018.
The oral presentations will be on the following dates:
A special congratulation goes our Director of Epidemiology: Suzanne Reed who will be presenting results on ‘Events associated with Nexplanon insertion and removal’ and our Director of Project Management, Christine Hagemann who will be presenting the final results on ‘EURAS-IUD contraceptive effectiveness’, both oral presentations are in process for publication.
Please note that the FIGO XXII RIO World Congress of Gynecology and Obstetrics will run from 14-19th October 2018 in Rio de Janeiro, Brazil. Please come and say hello if you also plan to attend.
With a view to the introduction of the GDPR/EUDSGVO we are glad to present our new updated privacy rules. The updated descriptions are stored under “about us” and then “privacy policy/GDPR”. Further translation for study participants will follow.
Congratulations to our Project Management team! In May 2018 they will be headed to Budapest to present at the European Society of Contraception. This year we are proud to announce that seven of our abstracts were accepted; two oral presentations and five posters – three with presentations during the conference proceedings. A big congratulations goes to the newest member or our Project Management team, Pauline De Corte, who’s secondary analysis of the EURAS-IUD data looking at differences in routine check-ups of IUDs was accepted as part of the young scientist session.
The European Society of Contraception will take place from 10-13th May, 2018 in Budapest, Hungary.
ZEG Berlin is growing… we are currently searching for analytical-minded, people with strong ethics and an interest in medical research to join our vibrant Berlin-based team. At ZEG Berlin we help pharmaceutical companies answer complex drug safety questions and stay abreast of an ever-changing regulatory environment. We’re passionate about data. We love numbers and we pride ourselves on developing strong collaborative relationships with everyone we work with.
At ZEG Berlin you will find a collaborative enviornment with a flat hierarchy and strong cross-functional study teams. We encourage career development through formal training, mentoring and attendance at academic and industry conferences and events. As a small company we look after our own, providing opportunities to balance work and home life, participate in post-graduate studies, travel or pursue your passionates away from the workplace.
To see our current list of open positions, check out our careers page here.
Our latest publication, Perforation risk and intra-uterine devices: results of the EURAS-IUD 5-year extension study, has just been published in the European Journal of Contraception and Reproductive Health Care. This landmark observational study followed women for 5 years and identified intra-uterine device (IUD) perforations dectected from 12 to 60 months following IUD insertion.
The incidence of uterine perforations in this study was low, although higher than the commonly reported rate. Clinical sequalae of perforations were generally mild and associated with a very low risk of injury. You can download the full text of article using this link: Full Article
We are delighted to be packing our bags again this summer and heading across the Atlantic to the International Society of Pharmacoepidemiology (ISPE) conference in Montreal, Canada. Our project management team will be presenting five posters and one oral presentation over the five days sharing the latest developments from our non-interventional, primary data driven studies.
We will also be sharing a booth with our friends and colleagues at Kantar Health. If you miss us during one of our sessions, come and find us in the exhibit hall.
Join ZEG Berlin at the 33rd International Conference on Pharmacoepidemiology and Clinical research in August, 2017.
We will have oral and poster presentations on our latest studies. Last year ZEG presented two oral presentations and three poster presentations. This year is set to be no different.
Our latest publication, Fertility and combined oral contraceptives – unintended pregnancies and planned pregnancies following oral contraceptive use – results from the INAS-SCORE study, was published in the European Journal of Contraception and Reproductive Health in October 2016. In this article we reviewed the secondary fertility outcomes from the INAS-SCORE study and compared United States and European data. Interestingly, even after excluding ‘improper use’ as a cause for unplanned pregnancy, US women were more likely to expereince unplanned pregnancies than their European counterparts – a result we still cannot explain.
Interested in accessing the full article? The first 50 readers can access the full article using this link.
With a view to the introduction of the GDPR/EUDSGVO we are glad to present our new
updated privacy policy . The updated description are stored under “about us” and then “privacy policy/GDPR”. Further translation for study participants will follow contemporary.